Terms: = Liver cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
465 results:
1. Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against liver cancer.
Chen S; Li M; Xue C; Zhou X; Wei J; Zheng L; Duan Y; Deng H; Tang F; Xiong W; Xiang B; Zhou M
Drug Des Devel Ther; 2024; 18():1321-1338. PubMed ID: 38681206
[TBL] [Abstract] [Full Text] [Related]
2. Apoptotic Effect of Isoimpertorin via Inhibition of c-Myc and SIRT1 Signaling Axis.
Ko HJ; Park SY; Sim DY; Kim SH; Hur S; Lee JH; Kim Y
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673833
[TBL] [Abstract] [Full Text] [Related]
3. Synthesis, bioactivity assessment, molecular docking and ADMET studies of new chromone congeners exhibiting potent anticancer activity.
Abo-Salem HM; El Souda SSM; Shafey HI; Zoheir KMA; Ahmed KM; Mahmoud K; Mahrous KF; Fawzy NM
Sci Rep; 2024 Apr; 14(1):9636. PubMed ID: 38671055
[TBL] [Abstract] [Full Text] [Related]
4. cdk4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
5. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract] [Full Text] [Related]
6. Anti-proliferative Effects of Pinocembrin Isolated From
Saengboonmee C; Thithuan K; Mahalapbutr P; Taebprakhon C; Aman A; Rungrotmongkol T; Kamkaew A; Schevenels FT; Chompupong T; Wongkham S; Lekphrom R
Integr Cancer Ther; 2024; 23():15347354241237519. PubMed ID: 38462928
[TBL] [Abstract] [Full Text] [Related]
7. Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study.
Li D; Jin Y; Lin M; Zeng C; Guo Q; Liu Y; Zhang J
Cancer Med; 2024 Feb; 13(4):e6762. PubMed ID: 38457252
[TBL] [Abstract] [Full Text] [Related]
8. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract] [Full Text] [Related]
9. Cepharanthine suppresses proliferation and metastasis and enhances apoptosis by regulating JAK2/Stat3 pathway in hepatocellular carcinoma.
Liang Y; Li J; Xu H; Pang M; Hu C; Weng X; Xie W
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):94-100. PubMed ID: 38279472
[TBL] [Abstract] [Full Text] [Related]
10. [Bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation in a Breast cancer Patient Treated with Chemotherapy and cdk4/6 Inhibitor].
Kume S; Makino T; Goto A; Onodera Y; Kudo S
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1331-1333. PubMed ID: 38247075
[TBL] [Abstract] [Full Text] [Related]
11. SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis.
Wang X; Zhang H; Guo Z; Wang J; Lu C; Wang J; Jin R; Mo Z
Aging (Albany NY); 2024 Jan; 16(1):348-366. PubMed ID: 38189879
[TBL] [Abstract] [Full Text] [Related]
12. Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes.
Wu H; Kren BT; Lane AN; Cassel TA; Higashi RM; Fan TWM; Scaria GS; Shekels LL; Klein MA; Albrecht JH
J Biol Chem; 2023 Dec; 299(12):105407. PubMed ID: 38152849
[TBL] [Abstract] [Full Text] [Related]
13. let-7g sensitized liver cancer cells to 5-fluorouracil by downregulating ABCC10 expression.
Chen Y; Zhang B; Zhong C; Zhou Y; Xue L; Luo C; Yi L; Gong Q; Long Y
Chem Biol Drug Des; 2024 Jan; 103(1):e14396. PubMed ID: 38054583
[TBL] [Abstract] [Full Text] [Related]
14. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Ablation of C/EBPα-p300 Pathway Blocks Development of Obese Pregnancy Associated liver Disorders in Offspring.
Hanlon MA; Gulati R; Johnston M; Fleifil Y; Rivas M; Timchenko NA
Cell Mol Gastroenterol Hepatol; 2024; 17(3):347-360. PubMed ID: 37967813
[TBL] [Abstract] [Full Text] [Related]
16. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract] [Full Text] [Related]
17. liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
Sozer Karadagli S; Gursoy P
J Oncol Pharm Pract; 2024 Mar; 30(2):404-407. PubMed ID: 37899576
[TBL] [Abstract] [Full Text] [Related]
18. Integrated analysis and validation of the TRIM28-H2AX-cdk4 diagnostic model assists to predict the progression of HCC.
Tian Q; Lu G; Ma Y; Ma L; Shang Y; Guo N; Huang Y; Zhu L; Du R
Aging (Albany NY); 2023 Oct; 15(24):14617-14650. PubMed ID: 37870748
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of the Effect of Perfluorohexane Sulfonate on the Proliferation of Human liver Cells.
Sim KH; Oh HS; Lee C; Eun H; Lee YJ
Int J Environ Res Public Health; 2023 Sep; 20(19):. PubMed ID: 37835138
[TBL] [Abstract] [Full Text] [Related]
20. TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways.
Zhang Y; Wang ZZ; Han AQ; Yang MY; Zhu LX; Pan FM; Wang Y
Hepatobiliary Pancreat Dis Int; 2024 Apr; 23(2):195-209. PubMed ID: 37806848
[TBL] [Abstract] [Full Text] [Related]
[Next]
